Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 331 full-time employees. The company went IPO on 2018-07-20. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. The company is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Follow-Up Questions
Who is the CEO of Replimune Group Inc?
Dr. Sushil Patel is the Chief Executive Officer of Replimune Group Inc, joining the firm since 2021.
What is the price performance of REPL stock?
The current price of REPL is $3.33, it has decreased 3.61% in the last trading day.
What are the primary business themes or industries for Replimune Group Inc?
Replimune Group Inc belongs to Biotechnology industry and the sector is Health Care
What is Replimune Group Inc market cap?
Replimune Group Inc's current market cap is $260.3M
Is Replimune Group Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Replimune Group Inc, including 3 strong buy, 4 buy, 7 hold, 1 sell, and 3 strong sell
